![]() | This article has not yet been rated on Wikipedia's content assessment scale. |
![]() | This edit request by an editor with a conflict of interest has now been answered. |
As an employee of Unity Biotechnology, I am proposing two changes to the current description of the company based on publicly available information.
1- the page currently states that has a product "in Phase I clinical trials as of September 2018" (second paragraph) Actually, the Phase 1 trial was initiated in June 2018, as reported on FightAging.org [1]. The company also issued a press release announcing the trial initiation. [2]I propose that this date be updated accordingly to state "as of June 2018..." 2- the page states that "Unity Biotechnology is a startup biotechnology company that aims to develop drugs which target senescent cells with the aim of extending life span." (paragraph 1) As noted in the company's S-1 SEC filing [3], the company's mission is to "extend human healthspan" not life span. As such, I propose replacing "life span" with "healthspan" so that the sentence reads: "Unity Biotechnology is a startup biotechnology company that aims to develop drugs which target senescent cells with the aim of extending healthspan." Bluealg ( talk) 21:30, 14 November 2018 (UTC)
References
![]() | This edit request by an editor with a conflict of interest was declined. |
Jw126 ( talk) 23:18, 26 January 2021 (UTC)
I wouldn't say it's unusual to document a drop or rise in price that received significant coverage in reliable, independent sources. Nearlyevil665 ( talk) 18:22, 3 February 2021 (UTC)